An in vitro study of a tetravalent recombinant EGFR bispecific (rEGFRbi) antibody targeting wild-type (wt) EGFR showed similar efficacy to other platforms [34], and a previous small phase 1 trial in pancreatic cancer showed durable responses in patients with no dose-limiting toxicities [126]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.